Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function
Therapeutic options in heavily pretreated relapsed/refractory multiple myeloma patients are often very limited because of impaired bone marrow function. Bendamustine is effective in multiple myeloma and has a favourable toxicity profile. We hypothesized that dose-intensified bendamustine (180 mg/m2,...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2016
|
| In: |
Hematological oncology
Year: 2016, Volume: 34, Issue: 4, Pages: 200-207 |
| ISSN: | 1099-1069 |
| DOI: | 10.1002/hon.2199 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1002/hon.2199 Verlag, Volltext: http://onlinelibrary.wiley.com/doi/10.1002/hon.2199/abstract 
|
| Author Notes: | Iris Breitkreutz, Natalia Becker, Axel. Benner, Florentina Kosely, Christoph Heining, Jens Hillengass, Gerlinde Egerer, Anthony D. Ho, Hartmut Goldschmidt, Marc S. Raab |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1564160270 | ||
| 003 | DE-627 | ||
| 005 | 20230427142049.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171006s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hon.2199 |2 doi | |
| 035 | |a (DE-627)1564160270 | ||
| 035 | |a (DE-576)494160276 | ||
| 035 | |a (DE-599)BSZ494160276 | ||
| 035 | |a (OCoLC)1340980263 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Breitkreutz, Iris |d 1970- |e VerfasserIn |0 (DE-588)124783309 |0 (DE-627)366051806 |0 (DE-576)186798725 |4 aut | |
| 245 | 1 | 0 | |a Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function |c Iris Breitkreutz, Natalia Becker, Axel. Benner, Florentina Kosely, Christoph Heining, Jens Hillengass, Gerlinde Egerer, Anthony D. Ho, Hartmut Goldschmidt, Marc S. Raab |
| 264 | 1 | |c 2016 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First published: 18 March 2015 | ||
| 500 | |a Gesehen am 06.10.2017 | ||
| 520 | |a Therapeutic options in heavily pretreated relapsed/refractory multiple myeloma patients are often very limited because of impaired bone marrow function. Bendamustine is effective in multiple myeloma and has a favourable toxicity profile. We hypothesized that dose-intensified bendamustine (180 mg/m2, day 1 and 2) followed by autologous blood stem cell support (ASCS) would improve bone marrow function with low post-transplant toxicity in patients with severely impaired haematopoiesis. We analyzed 28 consecutive myeloma patients, with a median of three prior lines of therapy (range 2-7), who had relapsed from the last treatment with very limited bone marrow function and were therefore ineligible for conventional chemotherapy, novel agents or trial enrolment. Dose-intensified bendamustine with ASCS improved haematopoiesis as reflected by increased platelet counts (median 40/nl vs 94/nl, p = 0.0004) and white blood cell counts (3.0/nl vs 4.8/nl, p = 0.02) at day +100. The median time until engraftment of platelets (>50/nl) was 11 days (0-24 days) and of white cell counts (>1.0/nl) 0 days (0-24 days). At least, a minimal response was achieved in 36% of patients. The disease stabilization rate was 50% while the median progression-free survival rate was limited to 2.14 months. Most importantly, patients were once again eligible for alternative treatments including enrolment into clinical trials. We conclude that dose-intensified bendamustine followed by ASCS is safe and feasible for multiple myeloma patients with very limited bone marrow reserve. Copyright © 2015 John Wiley & Sons, Ltd. | ||
| 650 | 4 | |a autologous blood stem cells | |
| 650 | 4 | |a bendamustine | |
| 650 | 4 | |a bone marrow function | |
| 650 | 4 | |a multiple myeloma | |
| 700 | 1 | |a Kosely, Florentina |d 1981- |e VerfasserIn |0 (DE-588)104461921X |0 (DE-627)772248486 |0 (DE-576)397987943 |4 aut | |
| 700 | 1 | |a Heining, Christoph |e VerfasserIn |0 (DE-588)1156392764 |0 (DE-627)1019233915 |0 (DE-576)502161981 |4 aut | |
| 700 | 1 | |a Hillengaß, Jens |d 1974- |e VerfasserIn |0 (DE-588)124918549 |0 (DE-627)368073823 |0 (DE-576)294568298 |4 aut | |
| 700 | 1 | |a Egerer, Gerlinde |e VerfasserIn |0 (DE-588)105502168X |0 (DE-627)792516745 |0 (DE-576)167430882 |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematological oncology |d New York, NY [u.a.] : Wiley Interscience, 1983 |g 34(2016), 4, Seite 200-207 |h Online-Ressource |w (DE-627)320412040 |w (DE-600)2001443-0 |w (DE-576)114617414 |x 1099-1069 |7 nnas |a Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function |
| 773 | 1 | 8 | |g volume:34 |g year:2016 |g number:4 |g pages:200-207 |g extent:8 |a Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hon.2199 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://onlinelibrary.wiley.com/doi/10.1002/hon.2199/abstract |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171006 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |e 910000PR124052460 |k 0/910000/ |p 10 |y j | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 998 | |g 105502168X |a Egerer, Gerlinde |m 105502168X:Egerer, Gerlinde |d 910000 |d 910100 |e 910000PE105502168X |e 910100PE105502168X |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 998 | |g 124918549 |a Hillengaß, Jens |m 124918549:Hillengaß, Jens |d 910000 |d 910100 |e 910000PH124918549 |e 910100PH124918549 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 998 | |g 1156392764 |a Heining, Christoph |m 1156392764:Heining, Christoph |d 910000 |d 910100 |e 910000PH1156392764 |e 910100PH1156392764 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 104461921X |a Kosely, Florentina |m 104461921X:Kosely, Florentina |d 910000 |d 910100 |e 910000PK104461921X |e 910100PK104461921X |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 124783309 |a Breitkreutz, Iris |m 124783309:Breitkreutz, Iris |d 910000 |d 910100 |e 910000PB124783309 |e 910100PB124783309 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1564160270 |e 2982882035 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function","title_sort":"Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function"}],"note":["First published: 18 March 2015","Gesehen am 06.10.2017"],"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"2016"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"part":{"volume":"34","extent":"8","pages":"200-207","year":"2016","issue":"4","text":"34(2016), 4, Seite 200-207"},"language":["eng"],"id":{"eki":["320412040"],"zdb":["2001443-0"],"issn":["1099-1069"],"doi":["10.1002/(ISSN)1099-1069"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"320412040","type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow functionHematological oncology","origin":[{"publisherPlace":"New York, NY [u.a.]","dateIssuedDisp":"1983-","publisher":"Wiley Interscience","dateIssuedKey":"1983"}],"pubHistory":["1.1983 -"],"note":["Gesehen am 27.02.08"],"title":[{"title":"Hematological oncology","title_sort":"Hematological oncology"}]}],"recId":"1564160270","physDesc":[{"extent":"8 S."}],"name":{"displayForm":["Iris Breitkreutz, Natalia Becker, Axel. Benner, Florentina Kosely, Christoph Heining, Jens Hillengass, Gerlinde Egerer, Anthony D. Ho, Hartmut Goldschmidt, Marc S. Raab"]},"id":{"eki":["1564160270"],"doi":["10.1002/hon.2199"]},"person":[{"family":"Breitkreutz","display":"Breitkreutz, Iris","role":"aut","given":"Iris"},{"family":"Kosely","display":"Kosely, Florentina","given":"Florentina","role":"aut"},{"role":"aut","given":"Christoph","display":"Heining, Christoph","family":"Heining"},{"family":"Hillengaß","display":"Hillengaß, Jens","role":"aut","given":"Jens"},{"display":"Egerer, Gerlinde","family":"Egerer","given":"Gerlinde","role":"aut"},{"family":"Ho","display":"Ho, Anthony Dick","role":"aut","given":"Anthony Dick"},{"given":"Hartmut","role":"aut","family":"Goldschmidt","display":"Goldschmidt, Hartmut"},{"role":"aut","given":"Marc-Steffen","display":"Raab, Marc-Steffen","family":"Raab"}],"language":["eng"]} | ||
| SRT | |a BREITKREUTDOSEINTENS2016 | ||